RT Journal Article
T1 Eradication of P. aeruginosa biofilm in endotracheal tubes based on lock therapy: results from an in vitro study
A1 Pérez Granda, María Jesús
A1 Latorre, María Consuelo
A1 Alonso, Beatriz
A1 Hortal Iglesias, Francisco Javier
A1 Samaniego, Rafael
A1 Bouza Santiago, Emilio
A1 Guembe, María
AB BackgroundDespite the several strategies available for the management of biofilm-associated ventilator-associated pneumonia, data regarding the efficacy of applying antibiotics to the subglottic space (SS) are scarce. We created an in vitro model to assess the efficacy of antibiotic lock therapy (ALT) applied in the SS for eradication of Pseudomonas aeruginosa biofilm in endotracheal tubes (ETTs).MethodsWe applied 2 h of ALT to a P. aeruginosa biofilm in ETTs using a single dose (SD) and a 5-day therapy model (5D). We used sterile saline lock therapy (SLT) as the positive control. We compared colony count and the percentage of live cells between both models.ResultsThe median (IQR) cfu counts/ml and percentage of live cells in the SD-ALT and SD-SLT groups were, respectively, 3.12 × 105 (9.7 × 104-0) vs. 8.16 × 107 (7.0 × 107-0) (p = 0.05) and 53.2% (50.9%-57.2%) vs. 91.5% (87.3%-93.9%) (p < 0.001). The median (IQR) cfu counts/ml and percentage of live cells in the 5D-ALT and 5D-SLT groups were, respectively, 0 (0-0) vs. 3.2 × 107 (2.32 × 107-0) (p = 0.03) and 40.6% (36.6%-60.0%) vs. 90.3% (84.8%-93.9%) (p < 0.001).ConclusionWe demonstrated a statistically significant decrease in the viability of P. aeruginosa biofilm after application of 5D-ALT in the SS. Future clinical studies to assess ALT in patients under mechanical ventilation are needed.
PB BioMed Central Ltd
SN 1471-2334
YR 2017
FD 2017-12-04
LK https://hdl.handle.net/20.500.14352/120276
UL https://hdl.handle.net/20.500.14352/120276
LA eng
NO Pérez-Granda MJ, Latorre MC, Alonso B, Hortal J, Samaniego R, Bouza E, et al. Eradication of P. aeruginosa biofilm in endotracheal tubes based on lock therapy: Results from an in vitro study. BMC Infectious Diseases. 2017;17(1).
NO M. Guembe cuenta con el respaldo del Programa Miguel Servet (ISCIII-MICINN, CP13/00268) del Fondo de Investigación en Salud (FIS) del Instituto de Salud Carlos III (ISCIII), Madrid, España. Beatriz Alonso cuenta con el apoyo de la Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid y del Fondo Social Europeo (PEJ15/BIO/AI-0406). El estudio fue financiado parcialmente por el Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa" y por subvenciones del Instituto de Investigación Sanitaria Gregorio Marañón (II-PI-MGR-2016).
DS Docta Complutense
RD 18 mar 2026